Business Weekly

Tuesday
May 13th
  • Login
  • Sign up
    Registration


    Fields marked with an asterisk (*) are required.
    Security Code: * This Field is required This Field IS visible on profile Information for: Security Code: : Enter Security Code from image
    Weekly digest
    Receive HTML?
    Name: * This Field is required This Field IS NOT visible on profile
    Username: * This Field is required This Field IS visible on profile Information for: Username: : Please enter a valid User Name. No spaces, more than 2 characters and contain 0-9,a-z,A-Z
    E-mail: * This Field is required This Field IS NOT visible on profile Information for: E-mail: : Please enter a valid e-mail address.
    Password: * This Field is required This Field IS NOT visible on profile Information for: Password: : Please enter a valid Password. No spaces, more than 6 characters and contain 0-9,a-z,A-Z
    Verify Password: * This Field is required This Field IS NOT visible on profile
    Company: * This Field is required This Field IS visible on profile
    Industry Sector: * This Field is required This Field IS visible on profile Information for: Industry Sector : Please choose one industry sector from the drop-down box.
    Address: This Field IS visible on profile
    City: This Field IS visible on profile
    Postal Code: This Field IS visible on profile
    Country: This Field IS visible on profile
    Phone #: This Field IS visible on profile
    Website: This Field IS visible on profile
    Keywords: This Field IS visible on profile Information for: Keywords : These keywords, describing your company, market sector or technology will enable other registered users of the website to make contact with you more easily. Separate each keyword with a comma.
     
    * This Field is required This Field is required | This Field IS visible on profile This Field IS visible on profile | This Field IS NOT visible on profile This Field IS NOT visible on profile | Information for: ? : Field description: Move mouse over icon Field description: Move mouse over icon
  • Search
Text size
  • Increase font size
  • Default font size
  • Decrease font size
HOME arrow Life Sciences arrow Acambis extends its £20m JE vaccine deal arrow Registration
Acambis extends its £20m JE vaccine deal
Written by Sam Fountain   
Thursday, 27 March 2008
Image
Japanese Encephalitis is transmitted by the Culex genus of mosquitoes which thrive in the rice fields of Asia.
World-leading vaccine maker, Acambis has announced an extension to last year's £20m licensing deal for its Japanese Encephalitis vaccine, ChimeriVax-JE with the vaccines division of the global pharma giant, sanofi-aventis.

The Cambridge-based company said that as a result of the extension, which sees the license grow to include India and the Indian subcontinent, Acambis will receive an upfront payment from sanofi pasteur, a milestone payment on licensure of the vaccine in India and royalties on sales in these territories.

"This extended agreement will enable both Acambis and sanofi pasteur to benefit from a more co-ordinated approach in the JE endemic region," said Acambis' CEO, Ian Garland.

"ChimeriVax-JE is an important vaccine for a devastating disease and we are keen to progress towards licensure as quickly as possible."

In February last year, Acambis announced that it had granted sanofi pasteur marketing, distribution and certain manufacturing rights to Acambis' single-dose ChimeriVax-JE vaccine against Japanese encephalitis, which excluded the US, India and the Indian subcontinent.

The UK firm had an existing agreement with Bharat Biotech for India and the subcontinent, which Acambis and Bharat Biotech have mutually agreed to terminate, and the rights to these territories have now been granted to sanofi pasteur.

Acambis said that Bharat Biotech has made a significant contribution towards the development of ChimeriVax-JE and has agreed to compensate the Indian biotech firm, with the net financial effect positive for Acambis.

As with the existing agreement, Acambis said that it will supply the vaccine in bulk to sanofi pasteur from its Canton, MA facility.

According to the World Health Organization, 30,000 to 50,000 people suffer from JE annually, mainly in Asia. During a recent epidemic in northern India and Nepal, JE killed more than 1,000 people, most of them children.
Trackback(0)
Comments (0)Add Comment

Write comment
This content has been locked. You can no longer post any comment.

busy
 
Like this story? Tag It:
DeliciousDelicious
DiggDigg
NewsVineNewsVine
RedditReddit
TechnoratiTechnorati
?
< Prev   Next >
[ Back ]

In this news category

Most Popular
146 seek new posts as UCB exits Cambridge 
Bird flu vaccine shows promise 
New technology 80 times more effective at detecting mad-cow disease in the food chain 
BIOTECH 2008 - MedImmune millions a tonic for Cambridge 
Back to the Fucshia as Fox backs plant bio 
Online antibodies business is booming 

Featured business directory listing


Kester Cunningham John...
www.kcj.co.uk
Category: Legal

Site

REGISTER
RSS
BUSINESS WEEKLY EPAPER
ARCHIVE
SEARCH NEWS
BUSINESS BOOKSHOP
CONTACT US

Upcoming events

View Business Weekly's calendar

Email bulletin

Enter your email address:

Delivered by FeedBurner

Featured Blog

CandidCapital blogs
  • Of Budgets and White Papers

    The 2008 UK Budget may have been a modest affair, but published with it were two documents with probably greater implications for the long-term performance of the innovation sector in the UK.

    Many of you reading through the coverage of Alistair Darling’s first Budget, delivered on 12th March 2008, may have been reminded of Claud Cockburn’s famous (spoof?) entry for the prize of most dull but accurate headline: ‘Small Earthquake in Chile, Not Many Dead’.

    read more